Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (hofbauer cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: darapladib, rilapladib | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 248 | 0.85 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 2727
Sealed predictions
- PLA2G7 in dopamine neurons, braak+0.18 (p 0.646) → -0.01 (p 0.982)receipt 2734
Swarm cases
receipt 2734: PLA2G7 in dopamine neurons, braak
- power
- full sample +0.16 (p 0.526, n 18), 95% CI -0.33 to +0.58. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.17 (p 0.498, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.08 (p 0.761, n 18). could be the mix.
- skeptic
- leave-one-out range +0.06 to +0.30, sign flips 0; without severely affected donors +0.16 (p 0.526, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PLA2G7 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts